Refocused Gambro plans dialyser production ramp-up
This article was originally published in Clinica
Following the announcement that it is to sell its US renal care service arm to DaVita, Sweden's Gambro has revealed plans to open a major new manufacturing site in North America. The decision to step up production capacity for synthetic dialysers reflects growing market demand for these devices over non-synthetic ones, as well as DaVita's commitment to source the majority of its dialysis products from Gambro for at least 10 years.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.